Kendal Svedeen – CEO
Garth Nicolson, PhD – Chief Scientific Consultant
Professor Garth Nicholson, Ph.D., a Nobel Prize nominee who would not only be involved in research and development but also instrumental in FDA presentations; Read more . . .
Ernie Pfadenhauer, MS – Senior Research Consultant
Ernie Pfadenhauer, MS, an accomplished pharmaceutical chemist heads new formula development, manufacturing controls analytical methodology and patent preparations Read more . . .
Gordon McLaren, MD – Clinical Research
Gordon McLaren, M.D., specialist in treating hemochromatosis and principal investigator in Phase II clinical trials for another drug used to treat hemochromatosis.
Evan Seigel, PhD – FDA Consultant
Evan Siegel, PhD, a former FDA review chemist who has extensive experience in FDA drug submissions and has worked for several large pharmaceutical companies on FDA regulatory affairs.
Jerry Silver, JD – Business Consultant
Jerry Silver has over 30 years of healthcare company building experience with particular emphasis on business strategy. Mr. Silver has been a financial and strategic consultant to emerging companies specializing in the technology and medical verticals.
Andy Chow – International Business Consultant
Andy Chow is an Asian immigrant entrepreneur who established over 70 US based businesses for various Asian groups. He is a business liaison to company officials and governments in Cambodia, China, Hong Kong, Shanghai and Macao. Mr. Chow has imported and exported health products to US and Asian countries. Mr. Chow was responsible for the exportation of Detoxamin chelation suppositories to Cambodia when it was available as a dietary supplement.
Robert Settineri, MS – Director of Research
Robert Settineri, M.S. was senior manager of biological research for Newport Pharmaceuticals, Inc. where he conducted extensive pre-clinical in-vitro and in-vivo research on an immunomodulator drug, Inosine Pranobex; he also assisted in the writing and assembly of an FDA New Drug Application (NDA) for the company. Robert then established and consulting company, Sierra Productions Research, LLC where he presently consults for bio-medial companies on product development, pre-clinical, and clinical research studies. He was a member of the Investigational Review Board (“IRB”) for the Institute for Molecular Medicine. Robert was responsible for design and coordination of all pre-clinical and clinical studies on the chelation suppository, Detoxamin and is a co-author of a book on detoxification and chelation suppositories. He holds two patents and has two patents pending.
Rita Ellithorpe, MD – Medical Director
Rita Ellithorpe, M.D., a physician who is board-certified in integrative medicine, has over 3,000 patients on Detoxamin® EDTA suppositories and plans to be responsible for clinical studies as well as interfacing with the FDA; Read more . . .
Indrian Pather – D. Pharm.
Indrian Pather – D. Pharm. Director of Research and Professor of Pharmaceutics, serving on numerous
committees, including Research Committee (Chair), Strategic Planning Committee, Scholarship and Awards Committee (Chair) and IRB (Vice Chair). Previously served as Department Chair and also Chair of Curriculum Committee. Consultant to the pharmaceutical industry with regard to novel dosage form development and patents.
Over a period of approximately 10 years in industry, held positions of increasing responsibility ranging from Senior Scientist to Director of Pharmaceutical Sciences at pharmaceutical companies. Responsibilities included in-house formulation development, scale up, technology transfer, establishing new labs and production suites (with engineers), patent writing and liaison with patent lawyers, analytical chemistry, and oversight of contract manufacturers. Approximately 15 years teaching experience prior to this: lab capabilities were greatly expanded, contract service to industry initiated, and helped plan major extensions to pharmacy building.
Christine McLaren, PhD – Research Consultant
Christine McLaren, Ph.D., a statistician with specialization in blood diseases and hemochromatosis, the subject of the Company’s NIH grant proposal.
MICHAEL J. RAM, Esq. D. Sc.
Following his undergraduate and graduate training as a chemical engineer Dr. Ram became a very successful research engineer at the corporate research laboratories of Celanese Corporation. As a senior engineer he was primary investigator on several research contracts with NASA and the Defense Nuclear Agency and the inventor on numerous patents regarding carbon fiber composites, polymeric engineering materials, unique fibers and biomaterials. He is an inventor on 20 US patents and several related foreign patents and continues to be an active inventor. After completing Law School in 1972, Dr. Ram was with the law firm of Brooks, Haidt & Haffner in New York and then joined C.R. Bard, Inc. as Patent Counsel where he was appointed to the additional position of Director of Technical Liaison. He subsequently held the position of General Counsel for Intermedics Intraocular and the Ophthalmics Division of Pharmacia, the Swedish Pharmaceutical company, was an Associate with the law firm of Sheldon & Mak and a named partner with the intellectual property firm of Arant, Kleinberg, Lerner & Ram where he practiced intellectual property law for 5 years prior to joining Loeb & Loeb in 1997. Since 1999 he has been senior counsel at Koppel, Patrick, Heybl & Dawson. He has taught Legal Aspects of Technology Transfer at UC Berkeley, presented workshops on licensing matters, written several published articles regarding intellectual property issues and has authored several chapters and acted as legal advisor for several different legal texts.